Respiratory Virus Season 2024-2025: RSV Immunization Update

• 2024

  Sign in to bookmark this resource.

  Sign in
• Sean O'Leary

---

Access Resources

• LectureEN

About

This webinar will delve into the latest AAP nirsevimab recommendations, focusing on the optimal administration timing. Furthermore, it will analyze the effectiveness of nirsevimab in reducing RSV-associated emergency department visits and hospitalizations specifically during the 2023-2024 RSV season. Gain valuable insights on how nirsevimab can potentially impact healthcare outcomes and strategies for combating RSV infections in high-risk populations.

---

Tags

Focus Area: Infectious Disease

Audiences: EMS Clinicians; Physicians

Emergency Management Stages: Mitigation; Response

Keywords: Antibodies, Monoclonal; Hospitalization; Immunization; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Risk Factors; Vaccination; Virus Diseases; Treatment Outcome; Emergency Service, Hospital

Institutions: American Academy of Pediatrics (AAP)

---

More like this

2024-2025 Respiratory Virus Season: COVID-19 Vaccine Update 2024 · American Academy of Pediatrics (AAP) Caring for Patients in Inpatient and Outpatient Settings During Episodes of Surge 2022 · American Academy of Pediatrics (AAP) Pediatric Anthrax Clinical Management 2014 · American Academy of Pediatrics (AAP)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---